menu
    • menu
    [{"orgOrder":0,"company":"FutureGen","sponsor":"Gracell Biotechnologies","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell and Gene therapy","year":"2021","type":"Collaboration","leadProduct":"Immune Cell Therapies","moa":"CLDN18.2","graph1":"Oncology","graph2":"Discovery Platform","graph3":"FutureGen","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"FutureGen \/ Gracell Biotechnologies","highestDevelopmentStatusID":"3","companyTruncated":"FutureGen \/ Gracell Biotechnologies"},{"orgOrder":0,"company":"FutureGen","sponsor":"AbbVie Inc","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"CHINA","productType":"Large molecule","year":"2024","type":"Licensing Agreement","leadProduct":"FG-M701","moa":"","graph1":"Gastroenterology","graph2":"Preclinical","graph3":"FutureGen","amount2":1.71,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Gastroenterology","amount2New":1.71,"dosageForm":"","sponsorNew":"FutureGen \/ AbbVie Inc","highestDevelopmentStatusID":"4","companyTruncated":"FutureGen \/ AbbVie Inc"}]

    Find Clinical Drug Pipeline Developments & Deals by FutureGen

    Menu

    FutureGen

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            FutureGen

                            China arrow
                            PharmaVenue
                            Not Confirmed

                            FutureGen

                            China arrow
                            PharmaVenue
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : FG-M701

                            Therapeutic Area : Gastroenterology

                            Study Phase : Preclinical

                            Sponsor : AbbVie Inc

                            Deal Size : $1,710.0 million

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            AbbVie and FutureGen Announce License Agreement to Develop Next-Generation Therapy for IBD

                            Details : Under the terms of the agreement, AbbVie will receive an exclusive global license to develop, manufacture, and commercialize FG-M701 for the treatment of inflammatory bowel disease.

                            Brand Name : FG-M701

                            Molecule Type : Large molecule

                            Upfront Cash : $150.0 million

                            June 13, 2024

                            Lead Product(s) : FG-M701

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : Preclinical

                            Sponsor : AbbVie Inc

                            Deal Size : $1,710.0 million

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            FutureGen

                            China arrow
                            PharmaVenue
                            Not Confirmed

                            FutureGen

                            China arrow
                            PharmaVenue
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Immune Cell Therapies

                            Therapeutic Area : Oncology

                            Study Phase : Discovery Platform

                            Sponsor : Gracell Biotechnologies

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Gracell Signs Exclusive License Agreement with FutureGen Biopharm to Develop Engineered Immune Cell Therapies ...

                            Details : The collaboration aims to leverage Gracell's extensive experience in immune cell therapy in synergy with FutureGen's fully human CLDN18.2 antibodies to develop, manufacture & commercialize novel immune cell therapies for the treatment of patients with CL...

                            Brand Name : Undisclosed

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Undisclosed

                            August 16, 2021

                            Lead Product(s) : Immune Cell Therapies

                            Therapeutic Area : Oncology

                            Highest Development Status : Discovery Platform

                            Sponsor : Gracell Biotechnologies

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth